Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Li-Ming Gan; Maria Lagerström-Fermér; Leif Carlsson; Cecilia Arfvidsson; Ann-Charlotte Egnell; Anna Rudvik; M Kjaer; Anna Collén; James D. Thompson; John L. Joyal

doi:https://doi.org/10.1038/s41467-019-08852-4

doi.org/10.1038/s41467-019-08852-4

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Li-Ming Gan

32

,

Maria Lagerström-Fermér

7

,

..., John L. Joyal

3

Nature Communications16.60

Volume: 10, Issue: 1

Published: Feb 20, 2019

Abstract

Chemically modified mRNA is an efficient, biocompatible modality for therapeutic protein expression. We report a first-time-in-human study of this modality, aiming to evaluate safety and potential therapeutic effects. Men with type 2 diabetes mellitus (T2DM) received intradermal injections of modified mRNA encoding vascular endothelial growth factor A (VEGF-A) or buffered saline placebo (ethical obligations precluded use of a non-translatable...

Paper Fields

Paper Details

Title

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

DOI

doi.org/10.1038/s41467-019-08852-4

Published Date

Feb 20, 2019

Journal

Nature Communications

Volume

10

Issue

1

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History